PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
This article was originally published in Pharmaceutical Approvals Monthly
Despite targeting an indication with a very small population, PTC Therapeutics has fully enrolled a pivotal trial for ataluren (PTC124), its potential disease-modifying therapy for Duchenne muscular dystrophy, and expects to produce top-line data early next year. Regulatory filings in the U.S. and EU could follow closely if the data are promising
You may also be interested in...
Six-minute walk test proves itself in boys’ genetic disease, too.
PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.
Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.